Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 6/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24667605 | 0.90 | KMT2A (0.58) | KMT2APOLBL3MBTL1MEN1TSHR | |
| SCHEMBL9594973 | 0.89 | KMT2A (0.57) | KMT2APOLBL3MBTL1MEN1TSHR | |
| SCHEMBL31703165 | 0.88 | KMT2A (0.56) | KMT2APOLBL3MBTL1MEN1TSHR | |
| SCHEMBL14468583 | 0.83 | KMT2A (1.00) | KMT2APOLBL3MBTL1MEN1TSHR | |
| SCHEMBL1837650 | 0.83 | ALDH1A1 (0.70) | KMT2APOLBL3MBTL1MEN1TSHR | |
| SCHEMBL31390722 | 0.83 | ALDH1A1 (0.70) | KMT2APOLBL3MBTL1MEN1TSHR | |
| SCHEMBL1289638 | 0.81 | L3MBTL1 (0.69) | KMT2AL3MBTL1MEN1KDM4EMAPT | |
| SCHEMBL7904920 | 0.81 | KMT2A (0.71) | KMT2APOLBL3MBTL1MEN1TSHR | |
| SCHEMBL24498940 | 0.81 | KMT2A (0.71) | KMT2APOLBL3MBTL1MEN1TSHR | |
| SCHEMBL9808278 | 0.79 | ALDH1A1 (0.55) | KMT2APOLBTSHRALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115108926-B | Intermediate compound for preparing erdasatinib and preparation method | 上海工程技术大学 | 2023-06-20 | — | — | CN | claimed |
| CN-115108926-A | Intermediate compound for preparing erdastinib and preparation method | 上海工程技术大学 | 2022-09-27 | — | — | CN | claimed |
| WO-2025229046-A1 | SUBSTITUTED HYDROQUINOLINES FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME | MOLIUS SAGLIK TEKNOLOJILERI ANONIM SIRKETI (TR) | 2025-11-06 | — | — | WO | disclosed |
| EP-4644375-A1 | SUBSTITUTED HYDROQUINOLINES FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME | Molius Saglik Teknolojileri Anonim Sirketi (TR) | 2025-11-05 | — | — | EP | disclosed |
| US-20240315994-A1 | SMALL MOLECULE MODULATORS OF FERROPTOSIS | ARPEGGIO BIOSCIENCES, INC. | 2024-09-26 | — | — | US | disclosed |
| CN-115108926-B | Intermediate compound for preparing erdasatinib and preparation method | 上海工程技术大学 | 2023-06-20 | — | — | CN | disclosed |
| CN-115108926-A | Intermediate compound for preparing erdastinib and preparation method | 上海工程技术大学 | 2022-09-27 | — | — | CN | disclosed |
| US-10954197-B2 | Cathepsin-D and angiogenesis inhibitors and compositions thereof for treating breast cancer | YOGEE'S BIOINNOVATIONS PRIVATE LIMITED (IN) | 2021-03-23 | — | — | US | disclosed |
| US-20210002337-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | THE SCRIPPS RESEARCH INSTITUTE | 2021-01-07 | — | — | US | disclosed |
| US-10781239-B2 | In vivo engineered cereblon protein | VIVIDION THERAPEUTICS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200216507-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. | 2020-07-09 | — | — | US | disclosed |
| US-20060009461-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | BHATIA PRAMILA A | 2006-01-12 | — | — | US | disclosed |
| EP-1509213-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | Abbott Laboratories (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-02-12 | — | — | US | disclosed |
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-11 | — | — | US | disclosed |
| WO-2003099266-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-12-04 | — | — | WO | disclosed |
| US-4567264-A | ADRENERGIC BLOCKING AGENTS | SYNTEX (U.S.A.) INC. (US) | 1986-01-28 | — | — | US | disclosed |
| US-4558129-A | Benzodioxanyl-hydroxyethylene-piperazinyl acetanilides which effect calcium entry and β-blockade | SYNTEX (U.S.A.) INC. (US) | 1985-12-10 | — | — | US | disclosed |
| US-4499100-A | CARDIOUVASCULAR DISORDERS | SYNTEX (U.S.A.) INC. (US) | 1985-02-12 | — | — | US | disclosed |
| EP-0126449-A1 | Cardioselective aryloxy- and arylthio-hydroxypropyl piperazinyl acetanilides wich affect calcium entry | SYNTEX (U.S.A.) INC. (US) | 1984-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | KMT2A 2169/4885POLB 3627/4885L3MBTL1 4477/4885 |
| US-20200216507-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | KMT2A 607/4885POLB 4179/4885L3MBTL1 167/4885 |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | KMT2A 2169/4885POLB 3627/4885L3MBTL1 4477/4885 |
| US-20240315994-A1 | SMALL MOLECULE MODULATORS OF FERROPTOSIS | GPX4, GPX1, AIFM2 | KMT2A 2780/4885POLB 3938/4885L3MBTL1 1305/4885 |
| US-20060009461-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | PDE12, NAAA, CYP19A1 | KMT2A 1792/4885POLB 3383/4885L3MBTL1 4625/4885 |
| US-20210002337-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | KMT2A 607/4885POLB 4179/4885L3MBTL1 167/4885 |
| US-10954197-B2 | Cathepsin-D and angiogenesis inhibitors and compositions thereof for treating breast cancer | CTSD, CTSF, CTSG | KMT2A 3304/4885POLB 3291/4885L3MBTL1 2229/4885 |
| US-10781239-B2 | In vivo engineered cereblon protein | CRBN, CDR2, DCUN1D4 | KMT2A 607/4885POLB 4179/4885L3MBTL1 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.